There should be little or no concern of toxicity among the many thousands of resveratrol supplement users as the drug used in the trial was just that; SRT501 is a drug synthesized by Sirtris Pharmaceuticals a division of Glaxo Smithkline. And though modeled after the resveratrol molecule because of the broad based therapeutic potential that organic resveratrol has exhibited, it is a chemically synthesized compound and not a natural plant substance.

Furthermore, the drug SRT501 was formulated at a strength exceeding 1,000 times that of typical resveratrol supplement doses, a level which is nearly impossible to attain through natural supplementation.
Resveratrol alone is known to exhibit profound anti-cancer properties and has been specifically proposed for treatment of myeloma because it exhibits multiple ways to block this form of cancer, including inhibition of new undesirable new blood vessels (angiogenesis), inhibition of tumor cell invasion, and works synergistically in bone tissue with vitamin D.

Additionally, evidence from numerous in vitro and in vivo studies involving many other forms of cancer including breast, colon, prostate, pancreatic and lung has confirmed resveratrol’s ability to inhibit cancer at all three stages of development (initiation, promotion (growth) and progression (spread); something no existing anti-cancer drug does.

Resveratrol is also known to have potent anti-inflammatory and antioxidant effects, to inhibit platelet aggregation and counter insulin resistance.
The anti-cancer effects of resveratrol at low doses have been demonstrated recently in studies concerning breast cancer conducted at the University of Nebraska and colon cancer at the University of California, Irvine.

The RESVANTAGE® brand resveratrol supplements are a low dose resveratrol supplement that has become the leading choice of MDs and Naturopaths for use in their practices due to its safety (low dose) and stability (ability to retain potency).
Although considered very safe and well tolerated, the long term effects of high dose resveratrol supplementation are unknown at this time and many practitioners prefer a conservative approach since there is now abundant evidence of efficacy at low doses.

Alzheimer’s disease is a type of dementia that steals people of their ability to recall and execute basic tasks, such as eating and dressing. There are no meds to subdue or correct this tragic and terminal disease.
Preventing the creation of fibrils and unwinding them once they congregate into plaques are the present concentration of efforts to fight this disease that attacks brain organisms. According to the Alzheimer’s Association, over five million people in the United States, alone, suffer from this disease.

The results from the experiment, which was published recently on the internet in the journal Neurotoxicology, concur with previous human epidemiology experiments that associate regular red wine consumption with a reduction in risk of developing dementia.

Scientists studied resveratrol’s effects on fibrils by adding one type of beta-amyloid (Aβ42) with it and then looking for protein aggregation. They discovered that the larger the dosage of resveratrol, the smaller the quantity of aggregation. Resveratrol dramatically decreased the aggregation by as much as ninety percent.
Resveratrol also triggered the beta-amyloid fibrils to break apart, suggesting it may have the probability to destroy plaque that has already formed.

Though amyloid plaques are a unique aspect of Alzheimer’s disease, it is not totally transparent how these plaques foment the dementia associated with the disease. There is some signs that the fibrils that aggregate into the distinctive plaques are not as toxic to the brain than the intermediate compounds called oligomers. Resveratrol didn’t reduce the creation of oligomers, although the researchers saw some evidence that resveratrol could inhibit their toxic affect on cells.

The National Canine Cancer Foundation is a nationwide, contribution funded, 501 (c)(3) non-profit corporation dedicated to eliminating Cancer as a major health issue in dogs by funding grants directly to Cancer researchers who are working to save lives, find cures, better treatments and accurate, cost effective diagnostic methods in dealing with Canine Cancer.

The purpose of the Foundation’s Research Grant Program is to encourage and provide grant support for basic, pre-clinical and clinical research in high impact and innovative cancer research, which is intended to develop innovative approaches to a cure, treatment, diagnosis or prevention of cancers in dogs. The program fosters collaboration between basic and clinical scientists with the intent of enhancing the transfer of basic research findings to clinical usefulness.

Gary D. Nice, the Founder, Director, President and Chief Executive Officer was devastated by the loss of three dogs to Cancer in three years. He found out during those heart wrenching times how much work needed to be done to fight cancer in dogs and how many dogs were dying every day, many prematurely, to cancer. At that point, he decided to dedicate the rest of his life and resources to finding a cure for canine cancer.

He states, “Resvantage Canine is a very promising product as resveratrol has shown efficacy in the prevention and treatment of many different types of cancers and it gives us all hope as we continue to work to find a cure.”

The core issue for future medical developments has been understanding not just the effects, but the processes that lead to them within the body. Resveratrol actually activates proteins called sirtuins in the body.

These proteins are gaining a somewhat mythical reputation, as they have been found to powerfully stave off many health problems, including diabetes, once they are switched on and pointed in the right direction. Therein lies the trick, with the targeting of sirtuins and the proper activation of them.

For diabetes, there is a particular class of sirtuins located in the brain that control and monitor glucose metabolism, a key issue with diabetes. Therefore researchers at the University of Texas Southwest Medical Center delivered resveratrol directly to the brains of mice. The targeted sirtuins were activated, and diabetic symptoms were improved, reducing high blood sugar and insulin levels.

This is a groundbreaking discovery, because it specifically shows the cause and effect process of resveratrol on a specific health problem, rather than just looking at the end result. Therefore instead of taking an all encompassing supplement, drugs can be developed in the future that specifically target sirtuins in the brain for Type 2 Diabetes patients, and those predisposed to the disease.

It also means that more specific work will be done to see which sitruins are activated by resveratrol to cause which effects. It’s a huge step to creating effective, reliable and safe resveratrol drugs that can combat some of the worst health problems on the planet. Thanks to this research at the University of Texas Southwest Medical Center, a resveratrol based medication for diabetes that targets sirtuins in the brain is now a real possibility.